1. Ibrutinib use, treatment duration, and concomitant medications in Australian patients with relapsed or refractory chronic lymphocytic leukaemia. (14th June 2022) Authors: Mulligan, Stephen P.; Opat, Stephen; Marlton, Paula; Kuss, Bryone; Gerungan, Poppy; Puig, Andrea; McGeachie, Marija; Tam, Constantine S. Journal: British journal of haematology Issue: Volume 198:Number 4(2022) Page Start: 790 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Real-world experience of Australian and New Zealand patients with chronic lymphocytic leukemia and mantle cell lymphoma accessing ibrutinib through a Named Patient Program. Issue 2 (28th January 2023) Authors: Mulligan, Stephen P.; Opat, Stephen; Cheah, Chan Y.; Kuss, Bryone; Hertzberg, Mark; Marlton, Paula; Poplar, Sarah; Puig, Andrea; McGeachie, Marija; Weinkove, Robert; Tam, Constantine S. Journal: Leukemia & lymphoma Issue: Volume 64:Issue 2(2023) Page Start: 312 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗